LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | PD0325901 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 3887 | 3970 | 0.9790 | 0.9683 |
BT-20 | PD0325901 | 0.04 | uM | LJP6 | 72 | hr | 1334 | 3800 | 3970 | 0.9571 | 0.9354 |
BT-20 | PD173074 | 0.04 | uM | LJP6 | 72 | hr | 1334 | 4140 | 3970 | 1.0427 | 1.0643 |
BT-20 | PD184352 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4104 | 3970 | 1.0336 | 1.0506 |
BT-20 | Pelitinib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 3996 | 3970 | 1.0063 | 1.0095 |
BT-20 | PF431396 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 3745 | 3970 | 0.9432 | 0.9144 |
BT-20 | PF477736 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 3517 | 3970 | 0.8859 | 0.8281 |
BT-20 | PF562271 | 0.04 | uM | LJP6 | 72 | hr | 1334 | 3725 | 3970 | 0.9381 | 0.9067 |
BT-20 | PHA-665752 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4086 | 3970 | 1.0290 | 1.0437 |
BT-20 | PHA-793887 | 0.04 | uM | LJP6 | 72 | hr | 1334 | 2521 | 3970 | 0.6349 | 0.4500 |
BT-20 | PI103 | 0.04 | uM | LJP6 | 72 | hr | 1334 | 3878 | 3970 | 0.9768 | 0.9650 |
BT-20 | PLX-4720 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4142 | 3970 | 1.0432 | 1.0650 |
BT-20 | QL-X-138 | 0.04 | uM | LJP6 | 72 | hr | 1334 | 3221 | 3970 | 0.8113 | 0.7158 |
BT-20 | QL-XII-47 | 0.04 | uM | LJP6 | 72 | hr | 1334 | 3356 | 3970 | 0.8453 | 0.7670 |
BT-20 | Radicicol | 0.04 | uM | LJP5 | 72 | hr | 1334 | 3362 | 3970 | 0.8468 | 0.7693 |
BT-20 | Radicicol | 0.04 | uM | LJP6 | 72 | hr | 1334 | 3774 | 3970 | 0.9506 | 0.9256 |
BT-20 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4094 | 3970 | 1.0310 | 1.0467 |
BT-20 | Ruxolitinib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4182 | 3970 | 1.0532 | 1.0801 |
BT-20 | XL147 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4181 | 3970 | 1.0529 | 1.0797 |
BT-20 | Saracatinib | 0.04 | uM | LJP6 | 72 | hr | 1334 | 3861 | 3970 | 0.9723 | 0.9583 |
BT-20 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 1334 | 4411 | 3970 | 1.1108 | 1.1669 |
BT-20 | Sirolimus | 0.04 | uM | LJP6 | 72 | hr | 1334 | 2522 | 3970 | 0.6351 | 0.4504 |
BT-20 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1334 | 3776 | 3970 | 0.9511 | 0.9263 |
BT-20 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4275 | 3970 | 1.0766 | 1.1154 |
BT-20 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4137 | 3970 | 1.0418 | 1.0630 |